Companies › Obsidian Therapeutics
1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Jun 2029.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| OBX-115 Autologous cell therapy manufactured from participant tumor sample | – | Phase 1 | Tumor Skin | Jun 2029 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06060613 | OBX-115 | Phase 1 | Tumor Skin | Oncology | Jun 2029 |
Cash of $0m on 2026-06-30; operating cash flow positive
Press releases filed as 8-K in the last year:
No annotated target.
–
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.